Physician profile
Basel Assaad
NPI 1154531937
$10,459.76
in general payments reported to CMS, 2019-2025
45 companies · $2,531 in 2025
The $2,531 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $3,059 · 2021: $586 · 2022: $176 · 2023: $1,348 · 2024: $2,380 · 2025: $2,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,259.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $4,857.45 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $631.82 | 2023-2025 | Botox, Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $433.28 | 2023-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Pfizer INC. | $408.28 | 2023-2025 | |
| Argenx US, INC. | $301.84 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $280.38 | 2024-2025 | |
| Lilly USA, LLC | $267.04 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $237.96 | 2023-2025 | |
| Celgene Corporation | $226.07 | 2023-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $200.26 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $193.42 | 2023-2024 | Aptiom |
| Aucta Pharmaceuticals, INC. | $191.78 | 2024-2025 | Motpoly Xr |
| Lundbeck LLC | $161.54 | 2023-2025 | Vyepti |
| E.R. Squibb & Sons, L.L.C. | $158.50 | 2022-2025 | Zeposia |
| Livanova USA, INC. | $145.08 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $137.37 | 2021 | |
| Allergan, INC. | $133.62 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Kyowa Kirin, INC. | $96.21 | 2023-2024 | Nourianz |
| Azurity Pharmaceuticals, INC. | $95.61 | 2024-2025 | Horizant |
| Otter Pharmaceuticals, LLC | $89.46 | 2025 | Sympazan |
| Alexion Pharmaceuticals, INC. | $88.72 | 2024-2025 | Ultomiris |
| Abbott Laboratories | $83.97 | 2022 | |
| Biogen, INC. | $75.43 | 2024-2025 | Skyclarys |
| Vanda Pharmaceuticals INC. | $74.99 | 2025 | Ponvory |
| Jazz Pharmaceuticals INC. | $73.87 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $68.37 | 2025 | |
| Tanabe Pharma America, INC. | $57.72 | 2025 | Radicava |
| Csl Behring | $54.30 | 2024-2025 | Hizentra |
| Corium, LLC | $54.20 | 2023 | Adlarity |
| Genentech USA, INC. | $48.34 | 2025 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $44.48 | 2023 | Ongentys, Ingrezza |
| Otsuka America Pharmaceutical, INC. | $43.93 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $42.13 | 2024 | Rytary |
| Genzyme Corporation | $41.59 | 2025 | |
| Neurelis, INC. | $40.45 | 2021-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $29.40 | 2025 | Inbrija, Ampyra, Xeomin |
| Octapharma USA, INC. | $25.11 | 2024 | Panzyga |
| Tg Therapeutics, INC. | $23.70 | 2023 | |
| Servier Pharmaceuticals LLC | $23.30 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $22.50 | 2025 | Dysport |
| Ani Pharmaceuticals, INC. | $20.46 | 2024 | Purified Cortrophin Gel |
| Mdd US Operations, LLC | $17.21 | 2022 | |
| Impel Pharmaceuticals INC. | $16.95 | 2023 | Trudhesa |
| Validus Pharmaceuticals LLC | $16.67 | 2023 | Equetro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Assaad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.